Annual Fecal Occult Blood Testing can be Safely Suspended for up to 5 Years after a Negative Colonoscopy in Asymptomatic Average-Risk Patients

American Journal of Gastroenterology

Volumn 110, Issue 9, 2015, Pages 1355-1358

  Liu, Jennifer ^a   Finkelstein, Steven ^a   François, Fritz ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADVANCED CANCER; AGED; ANALYTICAL EQUIPMENT; ARTICLE; ASYMPTOMATIC DISEASE; COLON ADENOMA; COLON CANCER; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FALSE POSITIVE RESULT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; OCCULT BLOOD TEST KIT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; TUMOR VOLUME; ADENOMA; AGE DISTRIBUTION; CAUSE OF DEATH; COLORECTAL NEOPLASMS; FOLLOW UP; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; TIME; TRENDS; UNITED STATES;

ADENOMA; AGE DISTRIBUTION; AGED; CAUSE OF DEATH; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEW YORK; OCCULT BLOOD; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; TIME FACTORS;

EID: 84941261151     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.234     Document Type: Article

References (28)

1. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627-37.
2. Zauber AG, Winawer SJ, O'Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366: 687-96.
3. Burt RW, Barthel JS, Dunn KB et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2 010; 8: 8-6 1.
4. Levin B, Lieberman DA, McFarland B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95.
5. Qaseem A, Denberg TD, Hopkins RH Jr. et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012; 156: 378-86.
6. Rex DK, Johnson DA, Anderson JC et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104: 739-50.
7. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124: 544-60.
8. Lieberman D, Nadel M, Smith RA et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc 2007; 65: 757-66.
9. Nadel MR, Berkowitz Z, Klabunde CN et al. Fecal occult blood testing beliefs and practices of U. S. primary care physicians: serious deviations from evidence-based recommendations. J Gen Intern Med 2010; 25: 833-9.
10. Winawer SJ, Zauber AG, Fletcher RH et al. Guidelines for colonoscopy surveillance aft er polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130: 1872-85.
11. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening among adults aged 50-75 years-United States, 2008. MMWR Morb Mortal Wkly Rep 2010; 59: 808-12.
12. Khatami S, Xuan L, Roman R et al. Modestly increased use of colonoscopy when copayments are waived. Clin Gastroenterol Hepatol 2012; 10: 761-66.
13. Klabunde CN, Lanier D, Breslau ES et al. Improving colorectal cancer screening in primary care practice: innovative strategies and future directions. J Gen Intern Med 2007; 22: 1195-205.
14. Steinwachs D, Allen JD, Barlow WE et al. National Institutes of Health state-of-the-science conference statement: Enhancing use and quality of colorectal cancer screening. Ann Intern Med 2010; 152: 663-7.
15. Centers for Disease Control and Prevention (CDC). Cancer screening- United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61: 41-5.
16. Fisher JA, Fikry C, Troxel AB. Cutting cost and increasing access to colorectal cancer screening: another approach to following the guidelines. Cancer Epidemiol Biomarkers Prev 2006; 15: 108-13.
17. Goodwin JS, Singh A, Reddy N et al. Overuse of screening colonoscopy in the Medicare population. Arch Intern Med 2011; 171: 1335-43.
18. Pignone M, Saha S, Hoerger T et al. Cost-eff ectiveness analyses of colorectal cancer screening: a systematic review for the U. S. Preventive Services Task Force. Ann Intern Med 2002; 137: 96-104.
19. Ahn SB, Han DS, Bae JH et al. Th e miss rate for colorectal adenoma determined by quality-adjusted, back-to-back colonoscopies. Gut Liver 2012; 6: 64-70.
20. Postic G, Lewin D, Bickerstaff C et al. Colonoscopic miss rates determined by direct comparison of colonoscopy with colon resection specimens. Am J Gastroenterol 2002; 97: 3182-5.
21. Rex DK, Cutler CS, Lemmel GT et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112: 24-8.
22. Velez JP, Schwesinger WH, Stauff er J et al. Bidirectional endoscopy in patients with fecal occult blood. Surg Endosc 2002; 16: 117-20.
23. Stray N, Weberg R. A prospective study of same day bi-directional endoscopy in the evaluation of patients with occult gastrointestinal bleeding. Scand J Gastroenterol 2006; 41: 844-50.
24. Alemayehu G, Jarnerot G. Same-day upper and lower endoscopy in patients with occult bleeding, melena, hematochezia, and/or microcytic anemia. A retrospective study of 224 patients. Scand J Gastroenterol 1993; 28: 667-72.
25. Ali M, Yaqub M, Haider Z et al. Yield of dual endoscopy for positive fecal occult blood test. Am J Gastroenterol 2003; 98: 82-5.
26. Allison JE, Tekawa IS, Ransom LJ et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155-9.
27. Park DI, Ryu S, Kim YH et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105: 2017-25.
28. Castiglione G, Zappa M, Grazzini G et al. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer 1996; 74: 141-4.